A Phase 3 interventional study of Follitropin Delta (FE 999049) and Follitropin Alfa (GONAL-F) in Infertility, sponsored by Ferring Pharmaceuticals. Completed at 13 sites in 11 countries. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2022-01-13.
Sponsored by Ferring Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing follitropin delta in Infertility — 1 open to participants now, 1 under way, none of them phase 3. follitropin delta · Infertility.
Among the 13 studies testing follitropin delta in Infertility, this one has the largest enrollment, is the only one that started in 2013, is one of 6 in phase 3, and was the 2nd registered.
2,089 studies on the registry are indexed under Infertility; 355 are open to participants now.
Browse Infertility studies →1 of the 13 studies testing follitropin delta in Infertility is open now, in 1 country. Recruiting first, the newest first:
Centre Hospitalier Intercommunal Creteil · Sites in France
Ages 18–38 · Women only
By country, each count listing its studies:
follitropin delta: first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.
This study: 18 Years to 40 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2013.
This study's enrollment of 1,329 is above the median of 134 across 1,414 interventional studies indexed under Infertility.
Median enrollment 220 across the 13 interventional studies. Of the 12 that completed or were terminated, 9 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 13 have an industry lead sponsor. The 4 most frequent:
Ferring Pharmaceuticals is the lead sponsor of 249 studies on the registry; 4 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 14 (93%) have results posted.
39 studies in Infertility by Ferring Pharmaceuticals: none open now, 2 under way, none of them phase 3. Of 35 finished, 18 (51%) have results posted.
Among the 39 studies in Infertility by Ferring Pharmaceuticals, this one has the largest enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2013, is one of 11 in phase 3, and was the 18th registered.
Ferring Pharmaceuticals’s Infertility studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing follitropin delta in Infertility, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Ferring Pharmaceuticals’s 39 in Infertility:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This trial investigates the effects of FE 999049 compared to GONAL-F.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Follitropin Delta (FE 999049)
Drug: Follitropin Delta (FE 999049)
Follitropin Alfa (GONAL-F)
Drug: Follitropin Alfa (GONAL-F)
Ongoing Pregnancy Rate
Ongoing pregnancy was defined as at least one intrauterine viable fetus 10-11 weeks after blastocyst transfer.
Time frame: 10-11 weeks after blastocyst transfer
Ongoing Implantation Rate
Ongoing implantation rate was defined as the number of intrauterine viable fetuses 10-11 weeks after transfer divided by number of blastocysts transferred.
Time frame: 10-11 weeks after blastocyst transfer
Vital Pregnancy Rate
Vital pregnancy was defined as at least one intrauterine gestational sac with fetal heart beat 5-6 weeks after blastocyst transfer.
Time frame: 5-6 weeks after blastocyst transfer
Implantation Rate
Implantation rate was defined as the number of gestational sacs 5-6 weeks after transfer divided by number of blastocysts transferred.
Time frame: 5-6 weeks after blastocyst transfer
Proportion of Subjects With Extreme Ovarian Responses, Defined as <4, ≥15 or ≥20 Oocytes Retrieved
Time frame: Day of oocyte retrieval
Proportion of Subjects With Early OHSS (Ovarian Hyperstimulation Syndrome) and/or Preventive Interventions for Early OHSS
The proportion of subjects with early OHSS, early OHSS of moderate or severe grade, preventive interventions for early OHSS, early OHSS and/or preventive interventions for early OHSS, and early OHSS of moderate or severe grade and/or preventive interventions for early OHSS are presented.
Time frame: ≤9 days after triggering of final follicular maturation
Proportion of Subjects With Cycle Cancellation Due to Poor Ovarian Response or Excessive Ovarian Response
Proportion of subjects with cycle cancellation due to poor ovarian response, excessive ovarian response, and triggering with gonadotropin-releasing hormone (GnRH) agonist are presented.
Time frame: End-of-stimulation (up to 20 stimulation days)
Number of Oocytes Retrieved
Time frame: Day of oocyte retrieval
Proportion of Subjects With <4, 4-7, 8-14, 15-19 and ≥20 Oocytes Retrieved
Time frame: Day of oocyte retrieval
Percentage of Metaphase II Oocytes (Oocytes Inseminated Using ICSI [Intracytoplasmic Sperm Injection])
Number of oocytes in metaphase II prior to ICSI insemination is presented.
Time frame: Prior to insemination
Fertilisation Rate
Fertilisation rate was defined as the number of oocytes with 2 pronuclei divided by the number of oocytes retrieved.
Time frame: Day 1 after insemination
Number and Quality of Embryos on Day 3
Number of embryos (total and good-quality) on Day 3 are presented. A good-quality embryo was defined as an embryo with ≥6 blastomeres and fragmentation ≤20% on Day 3.
Time frame: On day 3 after oocyte retrieval
Number and Quality of Blastocysts on Day 5
Number of blastocysts (total and good-quality) on Day 5 are presented. A good-quality blastocyst was defined as a blastocyst of grade 3BB or higher.
Time frame: On day 5 after oocyte retrieval
Total Gonadotropin Dose
The total gonadotropin dose was recorded.
Time frame: End-of-stimulation (up to 20 stimulation days)
Number of Stimulation Days
Time frame: End-of-stimulation (up to 20 stimulation days)
Proportion of Subjects With Investigator-requested Gonadotropin Dose Adjustments
Time frame: End-of-stimulation (up to 20 stimulation days)
Frequency of Injection Site Reactions (Redness, Pain, Itching, Swelling and Bruising) Assessed by the Subject During the Stimulation Period
Subjects self-assessed injection site reactions (redness, itching, pain, swelling and bruising) immediately, 30 minutes and 24 hours after each injection. The injection site reactions were assessed as none, mild, moderate and severe. The frequency of injection site reactions (mild, moderate or severe) based on all assessments performed is presented.
Time frame: End-of-stimulation (up to 20 stimulation days)
Abdominal Discomfort Related to Controlled Ovarian Stimulation as Assessed by a Visual Analogue Scale (VAS)
The subject self-assessed abdominal discomfort related to controlled ovarian stimulation using a VAS going from 0 mm (no abdominal discomfort) to 100 mm (worst imaginable abdominal discomfort).
Time frame: End-of-stimulation and day of blastocyst transfer
Changes in Body Weight
Change in body weight from baseline to end-of-stimulation and from baseline to day of blastocyst transfer.
Time frame: End-of-stimulation and day of blastocyst transfer
Changes in Maximum Abdominal Circumference
Change in maximum abdominal circumference from baseline to end-of-stimulation and from baseline to day of blastocyst transfer.
Time frame: End-of-stimulation and day of blastocyst transfer
Proportion of Subjects With Treatment-induced Anti-follicle-stimulating Hormone (FSH) Antibodies
The proportion of subjects with at least one treatment-induced anti-FSH antibody response at any time point.
Time frame: Stimulation day 1, 7-10 days after last FE 999049 or GONAL-F dose and 21-28 days after last FE 999049 or GONAL-F dose
Proportion of Subjects With Late OHSS
Late OHSS was defined as OHSS with onset \>9 days after triggering of final follicular maturation.The proportion of subjects with late OHSS, and late OHSS of moderate or severe grade are presented.
Time frame: >9 days after triggering of final follicular maturation
Technical Malfunctions of the Administration Pen
Confirmed technical malfunction of administration pen.
Time frame: End-of-stimulation (up to 20 stimulation days)
A total of 37 sites randomised subjects into the trial : 3 in Belgium, 3 in Brazil, 3 in Canada, 4 in the Czech Republic, 2 in Denmark, 2 in France, 2 in Italy, 2 in Poland, 4 in Russia, 10 in Spain and 2 in United Kingdom.
| Milestone | FE 999049 | GONAL-F |
|---|---|---|
| Started | 665 | 661 |
| Completed | 630 | 639 |
| Not completed | 35 | 22 |
| Withdrew: Protocol violation | 25 | 11 |
| Withdrew: Adverse event | 9 | 10 |
| Withdrew: Personal reasons | 1 | 1 |
Ongoing pregnancy was defined as at least one intrauterine viable fetus 10-11 weeks after blastocyst transfer.
| Percentage of subjects | FE 999049 | GONAL-F |
|---|---|---|
| Ongoing Pregnancy Rate | 30.7 | 31.6 |
Ongoing implantation rate was defined as the number of intrauterine viable fetuses 10-11 weeks after transfer divided by number of blastocysts transferred.
| Percentage | FE 999049 | GONAL-F |
|---|---|---|
| Ongoing Implantation Rate | 35.2 | 35.8 |
Vital pregnancy was defined as at least one intrauterine gestational sac with fetal heart beat 5-6 weeks after blastocyst transfer.
| Percentage of subjects | FE 999049 | GONAL-F |
|---|---|---|
| Vital Pregnancy Rate | 31.7 | 33.4 |
Implantation rate was defined as the number of gestational sacs 5-6 weeks after transfer divided by number of blastocysts transferred.
| Percentage | FE 999049 | GONAL-F |
|---|---|---|
| Implantation Rate | 39.8 | 41.3 |
| Percentage of subjects | FE 999049 | GONAL-F |
|---|---|---|
| <4 or >=15 oocytes retrieved | 26.6 | 31.3 |
| <4 or >=20 oocytes retrieved | 14.5 | 18.4 |
The proportion of subjects with early OHSS, early OHSS of moderate or severe grade, preventive interventions for early OHSS, early OHSS and/or preventive interventions for early OHSS, and early OHSS of moderate or severe grade and/or preventive interventions for early OHSS are presented.
| Percentage of subjects | FE 999049 | GONAL-F |
|---|---|---|
| Early OHSS (any grade) | 2.6 | 3.0 |
| Early OHSS (moderate/severe) | 1.4 | 1.4 |
| Any preventive intervention | 2.3 | 4.5 |
| Early OHSS (any grade) / preventive interventions | 4.7 | 6.2 |
| Early OHSS (mod/severe) / preventive interventions | 3.6 | 5.1 |
Proportion of subjects with cycle cancellation due to poor ovarian response, excessive ovarian response, and triggering with gonadotropin-releasing hormone (GnRH) agonist are presented.
| Percentage of subjects | FE 999049 | GONAL-F |
|---|---|---|
| Cycle cancelled due to poor ovarian response | 3.8 | 2.7 |
| Cycle cancelled due to excessive ovarian response | 0 | 0 |
| Triggering with GnRH agonist | 1.5 | 3.5 |
| Oocytes retrieved | FE 999049 | GONAL-F |
|---|---|---|
| Number of Oocytes Retrieved | 10.0 ± 5.6 | 10.4 ± 6.5 |
| Percentage of subjects | FE 999049 | GONAL-F |
|---|---|---|
| Low response (<4 oocytes) | 8.0 | 9.6 |
| Moderate response (4-7 oocytes) | 30.1 | 30.3 |
| Targeted response (8-14 oocytes) | 43.3 | 38.4 |
| Hyperresponse (15-19 oocytes) | 12.1 | 12.9 |
| Severe hyperresponse (≥ 20 oocytes) | 6.5 | 8.7 |
Number of oocytes in metaphase II prior to ICSI insemination is presented.
| Number of oocytes | FE 999049 | GONAL-F |
|---|---|---|
| Percentage of Metaphase II Oocytes (Oocytes Inseminated Using ICSI [Intracytoplasmic Sperm Injection]) | 7.4 ± 4.3 | 7.7 ± 5.2 |
Fertilisation rate was defined as the number of oocytes with 2 pronuclei divided by the number of oocytes retrieved.
| Percentage of oocytes | FE 999049 | GONAL-F |
|---|---|---|
| Fertilisation Rate | 56 ± 24.5 | 57 ± 23.8 |
Number of embryos (total and good-quality) on Day 3 are presented. A good-quality embryo was defined as an embryo with ≥6 blastomeres and fragmentation ≤20% on Day 3.
| Number of embryos | FE 999049 | GONAL-F |
|---|---|---|
| Number of embryos | 5.4 ± 3.7 | 5.7 ± 4.3 |
| Number of good-quality embryos | 4.2 ± 3.3 | 4.5 ± 3.7 |
Number of blastocysts (total and good-quality) on Day 5 are presented. A good-quality blastocyst was defined as a blastocyst of grade 3BB or higher.
| Number of blastocytss | FE 999049 | GONAL-F |
|---|---|---|
| Number of blastocysts | 3.3 ± 2.8 | 3.5 ± 3.2 |
| Number of good-quality blastocysts | 2.0 ± 2.2 | 2.1 ± 2.4 |
The total gonadotropin dose was recorded.
| µg of dose | FE 999049 | GONAL-F |
|---|---|---|
| Total Gonadotropin Dose | 90 ± 25.3 | 103.7 ± 33.6 |
| Days | FE 999049 | GONAL-F |
|---|---|---|
| Number of Stimulation Days | 8.9 ± 1.9 | 8.6 ± 1.7 |
| Percentage of subjects | FE 999049 | GONAL-F |
|---|---|---|
| Proportion of Subjects With Investigator-requested Gonadotropin Dose Adjustments | 33.2 | 36.8 |
Subjects self-assessed injection site reactions (redness, itching, pain, swelling and bruising) immediately, 30 minutes and 24 hours after each injection. The injection site reactions were assessed as none, mild, moderate and severe. The frequency of injection site reactions (mild, moderate or severe) based on all assessments performed is presented.
| Percentage of events | FE 999049 | GONAL-F |
|---|---|---|
| Frequency of Injection Site Reactions (Redness, Pain, Itching, Swelling and Bruising) Assessed by the Subject During the Stimulation Period | 3.4 | 3.5 |
The subject self-assessed abdominal discomfort related to controlled ovarian stimulation using a VAS going from 0 mm (no abdominal discomfort) to 100 mm (worst imaginable abdominal discomfort).
| Millimeter | FE 999049 | GONAL-F |
|---|---|---|
| End of stimulation visit | 16.1 ± 18.14 | 15.9 ± 17.36 |
| Transfer visit | 17.2 ± 20.02 | 16.1 ± 19.37 |
Change in body weight from baseline to end-of-stimulation and from baseline to day of blastocyst transfer.
| Kg | FE 999049 | GONAL-F |
|---|---|---|
| End of stimulation visit | 0.3 ± 1.11 | 0.2 ± 0.78 |
| Transfer visit | 0.0 ± 1.03 | 0.0 ± 0.98 |
Change in maximum abdominal circumference from baseline to end-of-stimulation and from baseline to day of blastocyst transfer.
| Centimeter | FE 999049 | GONAL-F |
|---|---|---|
| End of stimulation visit | 0.3 ± 4.41 | 0.1 ± 5.03 |
| Transfer visit | 0.6 ± 4.79 | -0.1 ± 5.23 |
The proportion of subjects with at least one treatment-induced anti-FSH antibody response at any time point.
| Percentage of subjects | FE 999049 | GONAL-F |
|---|---|---|
| Proportion of Subjects With Treatment-induced Anti-follicle-stimulating Hormone (FSH) Antibodies | 1.05 (0.42 to 2.16) | 0.76 (0.25 to 1.76) |
Late OHSS was defined as OHSS with onset \>9 days after triggering of final follicular maturation.The proportion of subjects with late OHSS, and late OHSS of moderate or severe grade are presented.
| Percentage of subjects | FE 999049 | GONAL-F |
|---|---|---|
| Late OHSS (any grade) | 0.9 | 1.8 |
| Late OHSS (moderate/severe) | 0.8 | 1.5 |
Confirmed technical malfunction of administration pen.
| Percentage of subjects | FE 999049 | GONAL-F |
|---|---|---|
| Technical Malfunctions of the Administration Pen | 0.15 | 0.00 |
Collected over Adverse events (AEs) were recorded from signed informed consent to the end-of-trial (up to approximately 5.5 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| FE 999049 | — | 16/665 (2.4%) | 168/665 (25.3%) |
| GONAL-F | — | 10/661 (1.5%) | 159/661 (24.1%) |
| Event | FE 999049 | GONAL-F |
|---|---|---|
| Ovarian hyperstimulation syndromeReproductive system and breast disorders | 3/665 | 6/661 |
| Haemorrhage in pregnancyPregnancy, puerperium and perinatal conditions | 5/665 | 1/661 |
| Biochemical pregnancyPregnancy, puerperium and perinatal conditions | 1/665 | 2/661 |
| Post procedural haemorrhageInjury, poisoning and procedural complications | 2/665 | 0/661 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 2/665 | 1/661 |
| Hyperemesis gravidarumPregnancy, puerperium and perinatal conditions | 0/665 | 1/661 |
| Post procedural infectionInfections and infestations | 0/665 | 1/661 |
| Abortion threatenedPregnancy, puerperium and perinatal conditions | 1/665 | 0/661 |
| Affect labilityPsychiatric disorders | 1/665 | 0/661 |
| Colitis ulcerativeGastrointestinal disorders | 1/665 | 0/661 |
| Event | FE 999049 | GONAL-F |
|---|---|---|
| HeadacheNervous system disorders | 97/665 | 88/661 |
| Procedural painInjury, poisoning and procedural complications | 49/665 | 52/661 |
| Pelvic painReproductive system and breast disorders | 46/665 | 41/661 |
| Pelvic discomfortReproductive system and breast disorders | 38/665 | 25/661 |
Of the 1,329 randomised subjects, 1,326 were exposed to IMP: FE 999049 (665 subjects) and GONAL-F (661 subjects). The 3 subjects who were not exposed to IMP were randomisation failures; 2 subjects (1 in each treatment group) did not fulfil an inclusion criterion, and 1 subject (in the GONAL-F group) withdrew due to personal reasons.
| Age, Categorical(Participants) | FE 999049 | GONAL-F | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 665 | 661 | 1326 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | FE 999049 | GONAL-F | Total |
|---|---|---|---|
| Female | 665 | 661 | 1326 |
| Male | 0 | 0 | 0 |
The record gives a start of Oct 2013, a primary completion of May 2015 and a completion of Jan 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2018, 3 years 4 months after primary completion. A results delay was requested in May 2016.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Follitropin delta